Search

Your search keyword '"Moy, B."' showing total 18 results
Start Over Author "Moy, B." Journal annals of oncology
18 results on '"Moy, B."'

2. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Author

Freedman, R.A., Heiling, H.M., Li, T., Trapani, D., Tayob, N., Smith, K.L., Davis, R., Pereslete, A.M., DeMeo, M.K., Cotter, C., Chen, W.Y., Parsons, H.A., Santa-Maria, C.A., Van Poznak, C., Moy, B., Brufsky, A.M., Melisko, M.E., O’Sullivan, C.C., Ashai, N., Rauf, Y., Nangia, J.R., Burns, R.T., Savoie, J., Wolff, A.C., Winer, E.P., Rimawi, M.F., Krop, I.E., and Lin, N.U.

Published
2024
Full Text
View/download PDF

3. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial

Author

Spring, L.M., primary, Tolaney, S.M., additional, Fell, G., additional, Bossuyt, V., additional, Abelman, R.O., additional, Wu, B., additional, Maheswaran, S., additional, Trippa, L., additional, Comander, A., additional, Mulvey, T., additional, McLaughlin, S., additional, Ryan, P., additional, Ryan, L., additional, Abraham, E., additional, Rosenstock, A., additional, Garrido-Castro, A.C., additional, Lynce, F., additional, Moy, B., additional, Isakoff, S.J., additional, Tung, N., additional, Mittendorf, E.A., additional, Ellisen, L.W., additional, and Bardia, A., additional

Published
2023
Full Text
View/download PDF

5. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Author

Delaloge, S., Cella, D., Ye, Y., Buyse, M., Chan, A., Barrios, C.H., Holmes, F.A., Mansi, J., Iwata, H., Ejlertsen, B., Moy, B., Chia, S.K.L., Gnant, M., Smichkoska, S., Ciceniene, A., Martinez, N., Filipović, S., Ben-Baruch, N.E., Joy, A.A., Langkjer, S.T., Senecal, F., de Boer, R.H., Moran, S., Yao, B., Bryce, R., Auerbach, A., Fallowfield, L., and Martin, M.

Published
2019
Full Text
View/download PDF

7. 45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial

Author

Chan, A., primary, Moy, B., additional, Mansi, J.L., additional, Gnant, M.I., additional, Barrios, C.H., additional, Separovic, R., additional, Guerrero-Zotano, A., additional, Gore, I., additional, Smith, J., additional, Bryce, R.P., additional, Xu, F., additional, Wong, A., additional, Martin, M., additional, and Holmes, F.A., additional

Published
2021
Full Text
View/download PDF

8. 358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer

Author

Bardia, A., primary, Spring, L.M., additional, Juric, D., additional, Partridge, A., additional, Ligibel, J., additional, Kuter, I., additional, Peppercorn, J., additional, Parsons, H., additional, Ryan, P., additional, Chawla, D., additional, Attaya, V., additional, Fitzgerald, D.M., additional, Viscosi, E., additional, Lormill, B., additional, Shellock, M., additional, Moy, B., additional, Tolaney, S.M., additional, and Ellisen, L.W., additional

Published
2020
Full Text
View/download PDF

10. 83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes

Author

Martin Jimenez, M., primary, Gnant, M.I., additional, Ejlertsen, B., additional, Mansi, J.L., additional, Ruiz-Borrego, M., additional, Jakobsen, E.H., additional, Osborne, C.K., additional, Birhiray, R., additional, Zhang, B., additional, Wong, A., additional, Moy, B., additional, and Holmes, F.A., additional

Published
2020
Full Text
View/download PDF

11. 1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial

Author

Saura, C., primary, Vivancos, A., additional, Matito, J., additional, Wildiers, H., additional, Brufsky, A.M., additional, Oliveira, M., additional, Waters, S., additional, Hurvitz, S.A., additional, Moy, B., additional, Kim, S-B., additional, Gradishar, W.J., additional, Queiroz, G.S., additional, Cronemberger, E., additional, Bebchuk, J., additional, Keyvanjah, K., additional, Lalani, A.S., additional, Eli, L.D., additional, and Delaloge, S., additional

Published
2020
Full Text
View/download PDF

12. Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer

Author

Fitzgerald, D.M., primary, Muzikansky, A., additional, Pinto, C., additional, Henderson, L., additional, Walmsley, C., additional, Allen, R., additional, Ferraro, G.B., additional, Isakoff, S., additional, Moy, B., additional, Oh, K., additional, Shih, H.A., additional, Dias-Santagata, D., additional, Iafrate, A.J., additional, Bardia, A., additional, Brastianos, P.K., additional, and Juric, D., additional

Published
2019
Full Text
View/download PDF

13. Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial

Author

Martin Jimenez, M., primary, Holmes, F.A., additional, Ejlertsen, B., additional, Delaloge, S., additional, Moy, B., additional, Iwata, H., additional, von Minckwitz, G., additional, Chia, S., additional, Mansi, J., additional, Barrios, C., additional, Gnant, M., additional, Tomasevic, Z., additional, Denduluri, N., additional, Separovic, R., additional, Kim, S-B., additional, Jakobsen, E.H., additional, Bryce, R.P., additional, Xu, F., additional, Buyse, M., additional, and Chan, A., additional

Published
2017
Full Text
View/download PDF

14. Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial

Author

Delaloge, S., primary, Ye, Y., additional, Cella, D., additional, Buyse, M., additional, Chan, A., additional, Barrios, C., additional, Holmes, F.A., additional, Mansi, J., additional, Iwata, H., additional, Ejlertsen, B., additional, Moy, B., additional, von Minckwitz, G., additional, Chia, S., additional, Gnant, M., additional, Smichkoska, S., additional, Ciceniene, A., additional, Moran, S., additional, Auerbach, A.H., additional, Fallowfield, L., additional, and Martin Jimenez, M., additional

Published
2017
Full Text
View/download PDF

18. immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

Author

Barroso-Sousa, R, Barry, W T, Guo, H, Dillon, D, Tan, Y B, Fuhrman, K, Osmani, W, Getz, A, Baltay, M, Dang, C, Yardley, D, Moy, B, Marcom, P K, Mittendorf, E A, Krop, I E, Winer, E P, and Tolaney, S M

Subjects
*HORMONE receptor positive breast cancer, *BREAST cancer, *EPIDERMAL growth factor receptors, *CLINICAL trial registries, *SECONDARY analysis, *BIOMARKERS
Abstract

Background Previous data suggest that the immune microenvironment plays a critical role in human epidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about the immune profiles of small HER2-positive tumors. In this study, we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (APT) trial and to correlate the immune markers with pathological and molecular tumor characteristics. Patients and methods The APT trial was a multicenter, single-arm, phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer. The study included 406 patients with HER2-positive, node-negative breast cancer, measuring up to 3 cm. Exploratory analysis of tumor infiltrating lymphocytes (TIL), programmed death-ligand 1 (PD-L1) expression (by immunohistochemistry), and immune gene signatures using data generated by nCounter PanCancer Pathways Panel (NanoString Technologies, Seattle, WA), and their association with pathological and molecular characteristics was carried out. Results Of the 406 patients, 328 (81%) had at least one immune assay carried out: 284 cases were evaluated for TIL, 266 for PD-L1, and 213 for immune gene signatures. High TIL (≥60%) were seen with greater frequency in hormone-receptor (HR) negative, histological grades 2 and 3, as well in HER2-enriched and basal-like tumors. Lower stromal PD-L1 (≤1%) expression was seen with greater frequency in HR-positive, histological grade 1, and in luminal tumors. Both TIL and stromal PD-L1 were positively correlated with 10 immune cell signatures, including Th1 and B cell signatures. Luminal B tumors were negatively correlated with those signatures. Significant correlation was seen among these immune markers; however, the magnitude of correlation did not indicate a monotonic relationship between them. Conclusion Immune profiles of small HER2-positive breast cancers differ according to HR status, histological grade, and molecular subtype. Further work is needed to explore the implication of these findings on disease outcome. Clinical trial registration clinicaltrials.gov identifier: NCT00542451. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results